Document is current
Any future updates will be listed below
-
Authors
Elms, Mark L. https://orcid.org/0000-0002-5185-5602
Jenks, Andrew D. https://orcid.org/0009-0005-1724-5412
Chowdhury, Avirup https://orcid.org/0000-0001-9817-0603
Krasny, Lukas
Chadha, Madhumeeta
Low, Kaan https://orcid.org/0000-0003-4275-660X
Harrison, Peter T.
Kerrison, William G.
Jones, Robin L.
Huang, Paul H. https://orcid.org/0000-0003-3972-5087
-
Funding
Funding for this research was provided by:
Sarcoma UK
DH | National Institute for Health Research
- License Information
-
More Information
Article History
Received: 1 March 2023
Accepted: 1 August 2025
First Online: 8 August 2025
Competing interests
: R.L.J. declares the receipt of grants and research support from M.S.D. and G.S.K., as well as receipt of consultation fees from Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks, SynOx, Tracon, and Upto Date. All other authors have no conflicts of interest to declare.
